Antiphospholipid syndrome (APS), characterized by antiphospholipid antibody (aPL)-driven thrombosis, is increasingly recognized as a critical etiology of catastrophic coronary events in young adults lacking traditional cardiovascular risk factors. This report delineates a 24-year-old male with left main coronary artery (LMCA) ST-segment elevation myocardial infarction (STEMI), managed through a novel strategy combining drug-coated balloon (DCB) angioplasty and APS-targeted pharmacotherapy (anticoagulation and immunomodulation). The case underscores the necessity of etiological exploration in young STEMI populations and challenges the conventional stent-based revascularization paradigm in hypercoagulable states. One-year follow-up demonstrated sustained patency without recurrent thrombosis, validating the efficacy of pathophysiology-guided interventions.
Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.
